


**Product Name** : LY2228820 dimesylate  
**Cat. No.** : PC-43421  
**CAS No.** : 862507-23-1  
**Molecular Formula** : C<sub>26</sub>H<sub>37</sub>FN<sub>6</sub>O<sub>6</sub>S<sub>2</sub>  
**Molecular Weight** : 612.737  
**Target** : p38 MAPK  
**Solubility** : DMSO: < 7.8 mg/mL



## Biological Activity

LY2228820 dimesylate (Ralimetinib) is a potent, selective, orally available inhibitor **p38 MAPK** with IC<sub>50</sub> of 5.3 and 3.2 nM for p38α and p38β, respectively.

LY2228820 dimesylate (Ralimetinib) potently and selectively inhibits phosphorylation of MK2 (Thr334) in anisomycin-stimulated HeLa cells and mouse RAW264.7 macrophages (IC<sub>50</sub>=35.3 nM), with no changes in phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

LY2228820 dimesylate (Ralimetinib) also reduces TNF-α secretion by LPS/IFN-γ-stimulated macrophages with IC<sub>50</sub> of 6.3 nM.

LY2228820 dimesylate (Ralimetinib) produces significant tumor growth delay in multiple in vivo cancer models (melanoma, non-small cell lung cancer, ovarian, glioma, myeloma, breast).

## References

- Tate CM, et al. *J Biol Chem*. 2013 Mar 1;288(9):6743-53.  
Campbell RM, et al. *Mol Cancer Ther*. 2014 Feb;13(2):364-74.  
Ishitsuka K, et al. *Br J Haematol*. 2008 May;141(5):598-606.  
Patnaik A, et al. *Clin Cancer Res*. 2016 Mar 1;22(5):1095-102.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com